Synthesis of poly(1, 2-glycerol carbonate)–paclitaxel conjugates and their utility as a single high-dose replacement for multi-dose treatment regimens in peritoneal cancer. Issue 12 (30th October 2017)

• Record Type: Journal Article
• Authors: Ekladious, Iriny; Liu, Rong; Zhang, Heng; Foil, Daniel H.; Todd, Daniel A.; Graf, Tyler N.; Padera, Robert F.; Oberlies, Nicholas H.; Colson, Yolonda L.; Grinstaff, Mark W.
• Is Part Of: Chemical science. Volume 8:Issue 12(2017)
• Page Start: 8443
• Page End: 8450
• Publication Date: 2017-10-30
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c7sc03501b
• Languages: English
• ISSNs: 2041-6520

Abstract

Abstract : A high drug-density, biodegradable polymeric nanocarrier replaces multi-dose paclitaxel treatment regimens. Abstract : Current chemotherapeutic dosing strategies are limited by the toxicity of anticancer agents and therefore rely on multiple low-dose administrations. As an alternative, we describe a novel sustained-release, biodegradable polymeric nanocarrier as a single administration replacement of multi-dose paclitaxel (PTX) treatment regimens. The first synthesis of poly(1, 2-glycerol carbonate)- graft -succinic acid-paclitaxel (PGC–PTX) is described, and its use enables high, controlled PTX loadings of up to 74 wt%. Moreover, the polymer backbone is composed of biocompatible building blocks—glycerol and carbon dioxide. When formulated as nanoparticles (NPs), PGC–PTX NPs exhibit PTX concentrations >15 mg mL −1, sub-100 nm diameters, narrow dispersity, storage stability for up to 6 months, and sustained and controlled PTX release kinetics over an extended period of 70 days. A safely administered single dose of PGC–PTX NPs contains more PTX than the median lethal dose of standard PTX. In murine models of peritoneal carcinomatosis, in which the clinical implementation of multi-dose intraperitoneal (IP) treatment regimens is limited by catheter-related complications, PGC–PTX NPs exhibit improved safety at high doses, tumor localization, and efficacy even after a single IP injection, with comparable curative effect to PTX administered as a multi-dose IP treatment regimen.